Asunaprevir

Asunaprevir
Clinical data
Other names	BMS-650032
ATC code	J05AP06 (WHO) ;
Identifiers
	IUPAC name tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;
CAS Number	630420-16-5;
PubChem CID	16076883;
IUPHAR/BPS	10882;
DrugBank	DB11586;
ChemSpider	17235944;
UNII	S9X0KRJ00S;
KEGG	D10093;
ChEBI	CHEBI:134723;
ChEMBL	ChEMBL2105735;
CompTox Dashboard (EPA)	DTXSID201026065 ;
ECHA InfoCard	100.206.482
Chemical and physical data
Formula	C35H46ClN5O9S
Molar mass	748.29 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C;
	InChI InChI=InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1; Key:XRWSZZJLZRKHHD-WVWIJVSJSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia^[1] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.^[2]

Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.^[3] Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.^[4]^[5]^[6]

References

^ "Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 26 August 2015.
^ "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov. 23 September 2015.
^ C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future. 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350.
^ Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. (January 2012). "Preliminary study of two antiviral agents for hepatitis C genotype 1". The New England Journal of Medicine. 366 (3): 216–24. doi:10.1056/NEJMoa1104430. PMID 22256805.
^ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. 19 April 2012.
^ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders Archived 2015-02-08 at the Wayback Machine. Highleyman, L. HIVandHepatitis.com. 8 November 2011.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] "Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 26 August 2015.

[2] "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov. 23 September 2015.

[3] C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future. 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350.

[4] Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. (January 2012). "Preliminary study of two antiviral agents for hepatitis C genotype 1". The New England Journal of Medicine. 366 (3): 216–24. doi:10.1056/NEJMoa1104430. PMID 22256805.

[5] "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. 19 April 2012.

[6] AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders Archived 2015-02-08 at the Wayback Machine. Highleyman, L. HIVandHepatitis.com. 8 November 2011.

[1]